

Bakers Union and FELRA Health and Welfare fund

Annual Review
January – December 2018

March 22, 2019

Presenters:
Holly Agoney: Account Executive
Adam Towner: Director, Client Management

Agenda

1. Key Performance Indicators...page 3

2. Three Period Trend...page 10

3. Cost Drivers...page 14

4. Supplemental...page 22

5. Clinical Opportunity/Vigilant Drug Program...page 24

6. Clinical Opportunity/Vigilant Drug Program (Rx OTC)...page 31

7. Clinical Opportunity/Diabetes Management Program...page 34

**8. Clinical Opportunity/
Utilization Management
Focus/Comprehensive...page 41**

9. Appendix...page 49

Your OptumRx Team



Holly Agoney

Strategic Account Executive



Aimee Cegelski

Pharmacy Account Manager



Fabian Gonzalez

Pharmacy Service Specialist





Adam Towner

Director, Client Management

1. Key Performance Indicators

Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17



plan performance - Bakers Union and FELRA Health and Welfare Fund


Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Description	Bakers Union and FELRA Health and Welfare Fund			Book of Business: Labor and Trust	
	Jan 18 - Dec 18	Jan 17 - Dec 17	Pct Change	Jan 18 - Dec 18	Pct Change
Average Eligible Members	752	774	-2.8%		
Average Age	41.0	41.2	-0.5%	38.1	0.1%
Total Plan Paid	\$969,529	\$910,277	6.5%		
Total Rxs	8,877	9,506	-6.6%		
Plan Paid PMPM	\$107.39	\$97.97	9.6%	\$65.76	3.7%
Plan Paid per Rx	\$109.22	\$95.76	14.1%	\$95.43	5.9%
Rxs PMPM	0.98	1.02	-3.9%	0.69	-2.1%
Member Paid Share	7.9%	9.1%	-13.0%	11.8%	-6.0%
Generic Dispensing Rate	83.8%	82.2%	2.0%	86.3%	0.3%
Mail Order Rate	1.2%	1.7%	-30.6%	7.6%	-1.3%
Average Days Supply	26.6	26.8	-0.7%	35.5	1.8%
Specialty Plan Paid PMPM	\$42.39	\$31.08	36.4%	\$23.79	10.5%
Percent of Specialty Plan Paid	39.5%	31.7%	24.4%	36.2%	6.5%


1. Key Performance Indicators - Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Client Trend



Specialty: Greatest PMPM Change of \$11.31



Plan Paid PMPM

Specialty/Traditional			
Claim Type	Jan 18 - Dec 18	Jan 17 - Dec 17	Percent Change
Specialty	\$42.39	\$31.08	36.4%
Traditional	\$65.00	\$66.89	-2.8%
All Drugs	\$107.39	\$97.97	9.6%

Traditional			
Claim Type	Jan 18 - Dec 18	Jan 17 - Dec 17	Percent Change
Brand	\$41.49	\$43.17	-3.9%
Generic	\$23.51	\$23.72	-0.9%
Traditional	\$65.00	\$66.89	-2.8%

traditional vs specialty - Bakers Union and FELRA Health and Welfare Fund


Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Description	Traditional			Specialty		
	Jan 18 -	Jan 17 -	Pct	Jan 18 -	Jan 17 -	Pct
	Dec 18	Dec 17	Change	Dec 18	Dec 17	Change
Average Eligible Members	752	774	-2.8%	752	774	-2.8%
Total Plan Paid	\$586,800	\$621,474	-5.6%	\$382,729	\$288,804	32.5%
Percent of Total Plan Paid	60.5%	68.3%	-11.3%	39.5%	31.7%	24.4%
Total Rx's	8,810	9,442	-6.7%	67	64	4.7%
Plan Paid PMPM	\$65.00	\$66.89	-2.8%	\$42.39	\$31.08	36.4%
Plan Paid per Rx	\$66.61	\$65.82	1.2%	\$5,712.38	\$4,512.56	26.6%
Rx's PMPM	0.98	1.02	-4.0%	0.007	0.007	7.7%
Generic Dispensing Rate	84.3%	82.6%	2.0%	22.4%	20.3%	10.2%
Member Paid Share	12.2%	12.6%	-3.2%	0.6%	0.7%	-14.8%
Member Paid per Rx	\$9.23	\$9.47	-2.5%	\$34.45	\$31.97	7.8%


1. Key Performance Indicators - Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

GDR



GDR increase of 1.6% equals a savings of \$38,601



Top Classes GDR Increase

Class	Jan 18 - Dec 18	Jan 17 - Dec 17	Increase
Impotence Agents	65.1%	3.1%	62.1%
Oral Anticoagulants	78.1%	54.8%	23.2%
Proton Pump Inhibitors	80.4%	69.1%	11.4%

1. Key Performance Indicators - Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Member Summary

752


Average Eligible Members

22

less than
previous

**20.1% of members using maintenance drugs
are being treated for 4 or more disease
categories**


Members and Utilizers Over Time



Age Bands PMPM

Age Band	Plan Paid PMPM			BOB Age Adjusted PMPM
	Male	Female	Total	
< 10	\$0.72	\$1.07	\$1.79	\$1.06
10 - 19	\$0.84	\$1.19	\$2.04	\$2.88
20 - 34	\$1.86	\$8.68	\$10.55	\$5.83
35 - 44	\$0.81	\$1.52	\$2.33	\$5.91
45 - 54	\$4.31	\$14.14	\$18.45	\$23.97
55 - 64	\$23.98	\$34.77	\$58.75	\$37.86
65 - 74	\$9.02	\$2.11	\$11.13	\$7.54
75 - 84	\$0.92	\$0.00	\$0.92	\$1.32
85 +	\$1.43	\$0.00	\$1.43	\$0.34

% of Members by Disease Category Maintenance Drugs




2. Three Period Trend

3. Multi-Period Trend - Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Plan Paid PMPM Breakdown




PMPM Trend	Brand	Generic	Specialty
Jan 18 - Dec 18 v Jan 17 - Dec 17	-3.9%	-0.8%	36.4%
Jan 17 - Dec 17 v Jan 16 - Dec 16	2.7%	7.3%	-20.8%
Average Trend	-0.6%	3.3%	7.8%

3. Multi-Period Trend - Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Plan Paid Distribution




Total Plan Paid	Jan 18 - Dec 18				Jan 17 - Dec 17				Jan 16 - Dec 16			
	Utilizers	Plan Paid per Utilizer	% Util	% Paid	Utilizers	Plan Paid per Utilizer	% Util	% Paid	Utilizers	Plan Paid per Utilizer	% Util	% Paid
\$0	57	\$0	11.0%	0.0%	64	\$0	11.9%	0.0%	73	\$0	13.9%	0.0%
>\$0 - \$1.9K	386	\$393	74.5%	15.7%	385	\$372	71.3%	15.8%	365	\$392	69.3%	14.8%
\$2K - \$4.9K	37	\$3,082	7.1%	11.6%	46	\$3,131	8.5%	15.8%	51	\$3,074	9.7%	16.2%
\$5K - \$9.9K	18	\$6,978	3.5%	13.0%	27	\$7,043	5.0%	20.9%	24	\$7,041	4.6%	17.5%
\$10K - \$14.9K	9	\$12,911	1.7%	12.0%	8	\$12,335	1.5%	10.9%	6	\$13,060	1.1%	8.1%
\$15K - \$24.9K	6	\$18,026	1.2%	11.2%	5	\$19,505	0.9%	10.7%	3	\$19,144	0.6%	6.0%
\$25K - \$49.9K	1	\$36,472	0.2%	3.8%	2	\$31,590	0.4%	7.0%	4	\$37,777	0.8%	15.7%
\$50K - \$99.9K	3	\$66,019	0.6%	20.4%	3	\$57,374	0.6%	18.9%	0	\$0	0.0%	0.0%
\$100K +	1	\$119,009	0.2%	12.3%	0	\$0	0.0%	0.0%	1	\$209,419	0.2%	21.7%

3. Multi-Period Trend - Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Specialty Plan Paid PMPM Breakdown - High Cost Utilizers vs Non High Cost Utilizers



Specialty Utilizers			
Period	High Cost	Non High Cost	Total
Jan 18 - Dec 18	5	6	11
Jan 17 - Dec 17	4	11	15
Jan 16 - Dec 16	4	8	12

Specialty Utilizer Trend				Specialty PMPM Trend		
Period	High Cost	Non High Cost	Total	High Cost	Non High Cost	Total
Jan 18 - Dec 18 v Jan 17 - Dec 17	25.0%	-45.5%	-26.7%	73.6%	-46.1%	36.4%
Jan 17 - Dec 17 v Jan 16 - Dec 16	0.0%	37.5%	25.0%	-33.5%	27.2%	-20.8%
Average Trend	12.5%	-4.0%	-0.8%	20.1%	-9.4%	7.8%

5 Specialty High Cost Utilizers in the current period represented 45.5% of specialty utilizers and 87.7% of total Specialty Plan Paid

High Cost Utilizer is an individual utilizer with average monthly Plan Paid specialty spend of >=\$2,500 within the given reporting period

3. Cost Drivers

Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

\$107.40 Current Plan Paid PMPM	\$97.97 Previous Plan Paid PMPM	\$9.42 Plan Paid PMPM Change	9.6% Plan Paid PMPM Pct Change
--	--	---	---



Cost Drivers

Rx Count	Drug Mix	Quantity	Unit Cost
-5.8%	11.4%	0.6%	3.5%

4a. Driver Analytics - Bakers Union and FELRA Health and Welfare Fund


Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Traditional and Specialty Plan Paid PMPM




Most Significant Driver: Rx Count
5.4% decrease

Traditional



Most Significant Driver: Drug Mix
31.2% increase

Specialty



top therapy class by plan paid - Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Curr Rank	Prev Rank	Therapeutic Class Name	Jan 18 - Dec 18								
			Plan Paid	Utilizers	Rxs	Plan Paid per Rx	GDR	Plan Paid PMPM	Avg Plan Paid Pct Change	Rxs PMPM Pct Change	Plan Paid PMPM Pct Change
1	1	Chronic Inflammatory Disease	\$191,522	5	30	\$6,384.05	3.3%	\$21.21	27.4%	-0.4%	26.9%
2	5	Oncology ▲	\$119,543	5	39	\$3,065.21	74.4%	\$13.24	306.6%	-16.4%	240.0%
3	3	Insulin	\$65,617	17	125	\$524.94	0.0%	\$7.27	7.7%	-0.3%	7.4%
4	4	Impotence Agents	\$33,669	22	129	\$261.00	65.1%	\$3.73	-8.6%	1.3%	-7.3%
5	2	Hepatitis C	\$32,304	1	1	\$32,304.00	0.0%	\$3.58	0.0%	-48.5%	-48.5%
6	8	Inhaled Asthma/COPD Combo	\$30,530	14	78	\$391.41	1.3%	\$3.38	21.7%	-0.9%	20.6%
7	7	DPP-4 Inhibitors & Combos	\$26,329	8	65	\$405.07	0.0%	\$2.92	3.8%	-5.8%	-2.2%
8	14	Atypical Antipsychotics	\$24,605	7	34	\$723.68	67.6%	\$2.73	37.0%	16.6%	59.8%
9	11	Anticonvulsants - 2nd Generation	\$24,481	39	224	\$109.29	75.4%	\$2.71	10.1%	16.4%	28.2%
10	22	HIV-Multiclass Combo ▲	\$23,878	1	8	\$2,984.72	0.0%	\$2.64	1.5%	105.8%	109.0%
Totals:			\$572,479		733	\$781.01	41.9%	\$63.41	23.8%	4.0%	28.8%
Plan Totals:			\$969,529		8,877	\$109.22	83.8%	\$107.39	14.1%	-3.9%	9.6%

▲ Has moved up in rank

top traditional drugs by plan paid - Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Curr Rank	Prev Rank	Drug Name	Therapeutic Class Name	Jan 18 - Dec 18							
				Plan Paid	Utilizers	Rxs	Plan Paid Per Rx	Plan Paid PMPM	Rxs PMPM Pct Change	Plan Paid PMPM Pct Change	Pct Total Plan Paid
1	1	HUMALOG MIX 50/50 KWIKPEN ←	Insulin	\$25,564	2	26	\$983.21	\$2.83	-13.7%	37.6%	4.4%
2	3	LYRICA	Anticonvulsants - 2nd Generation	\$18,064	7	45	\$401.43	\$2.00	5.3%	12.5%	3.1%
3	2	CIALIS	Impotence Agents	\$14,123	9	42	\$336.27	\$1.56	-40.0%	-21.7%	2.4%
4	126	SILDENAFIL CITRATE generic viagra	Impotence Agents	\$13,975	13	67	\$208.59	\$1.55	1,623.8%	1,025.4%	2.4%
5	7	ARIPRAZOLE	Atypical Antipsychotics	\$13,658	3	12	\$1,138.17	\$1.51	208.7%	28.9%	2.3%
6	24	JARDIANCE ←	SGLT-2 Inhibitors & Combos	\$12,912	3	29	\$445.26	\$1.43	86.5%	101.8%	2.2%
7	35	REXULTI	Atypical Antipsychotics	\$10,816	1	11	\$983.29	\$1.20	88.7%	131.3%	1.8%
8	20	INVOKANA ←	SGLT-2 Inhibitors & Combos	\$9,894	2	17	\$582.02	\$1.10	-2.8%	40.8%	1.7%
9	5	JANUVIA ←	DPP-4 Inhibitors & Combos	\$9,818	3	24	\$409.09	\$1.09	-22.8%	-15.1%	1.7%
10	10	LIDOCAINE	Local Anesthetics - Topical	\$9,011	11	27	\$333.75	\$1.00	11.1%	-0.3%	1.5%
11	22	VICTOZA ←	Injectable Diabetic Meds	\$8,970	1	12	\$747.48	\$0.99	-5.0%	35.8%	1.5%
12	6	SYMBICORT	Inhaled Asthma/COPD Combo	\$8,935	8	29	\$308.11	\$0.99	-21.5%	-16.9%	1.5%
13	38	BREO ELLIPTA	Inhaled Asthma/COPD Combo	\$8,834	4	22	\$401.55	\$0.98	50.9%	108.3%	1.5%
14	191	BYDUREON PEN ←	Injectable Diabetic Meds	\$8,292	1	13	\$637.83	\$0.92	1,237.9%	1,319.0%	1.4%
15	8	JANUMET ←	DPP-4 Inhibitors & Combos	\$7,684	2	19	\$404.40	\$0.85	-6.9%	-24.8%	1.3%
16	16	DEXILANT	Proton Pump Inhibitors	\$6,885	3	28	\$245.88	\$0.76	-22.1%	-16.8%	1.2%
17		HUMULIN R U-500 KWIKPEN ←	Insulin	\$6,704	1	7	\$957.78	\$0.74			1.1%
18	37	ADV AIR DISKUS	Inhaled Asthma/COPD Combo	\$6,469	1	13	\$497.62	\$0.72	11.5%	49.4%	1.1%
19		ABSORICA	Acne Products	\$6,415	1	3	\$2,138.17	\$0.71			1.1%
20	28	ADV AIR HFA	Inhaled Asthma/COPD Combo	\$6,271	2	13	\$482.38	\$0.69	2.9%	11.0%	1.1%
Totals:				\$213,295		459	\$464.69	\$23.63	17.5%	38.6%	36.3%
Traditional Plan Totals:				\$586,800		8,810	\$66.61	\$65.00	-4.0%	-2.8%	

← Diabetic meds -8 out of the top 20 are diabetic medications
 These 8 meds equal \$89,838 of your top 20 traditional plan spend and 15% of your total traditional plan spend and 10% of total plan spend.

top specialty drugs by plan paid - Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17





Curr Rank	Prev Rank	Drug Name	Therapeutic Class Name	Jan 18 - Dec 18							
				Plan Paid	Utilizers	Rxs	Plan Paid Per Rx	Plan Paid PMPM	Rxs PMPM Pct Change	Plan Paid PMPM Pct Change	Pct Specialty Plan Paid
1	3	IBRANCE	Oncology	\$118,957	1	10	\$11,895.74	\$13.18	243.0%	255.0%	31.1%
2		TREMFYA *	Chronic Inflammatory Disease	\$94,795	2	9	\$10,532.77	\$10.50			24.8%
3	1	HUMIRA PEN	Chronic Inflammatory Disease	\$38,548	2	8	\$4,818.49	\$4.27	-54.3%	-50.3%	10.1%
4	2	HARVONI	Hepatitis C	\$32,304	1	1	\$32,304.00	\$3.58	-48.5%	-48.5%	8.4%
5	8	XELJANZ XR	Chronic Inflammatory Disease	\$29,813	1	7	\$4,259.02	\$3.30	140.1%	162.1%	7.8%
6	7	STRIBILD	HIV-Multiclass Combo	\$23,878	1	8	\$2,984.72	\$2.64	105.8%	109.0%	6.2%
7		SIMPONI ARIA *	Chronic Inflammatory Disease	\$21,274	1	3	\$7,091.24	\$2.36			5.6%
8	14	TENOFOVIR DISOPROXIL FUMARATE	HIV-NRTI	\$8,547	1	11	\$777.04	\$0.95			2.2%
9		OTEZLA *	Chronic Inflammatory Disease	\$6,786	1	2	\$3,392.85	\$0.75			1.8%
10	12	BOTOX	Muscle Relaxants & Combos	\$4,915	1	4	\$1,228.71	\$0.54	311.7%	315.7%	1.3%
11	10	MYCOPHENOLATE MOFETIL	Immunosuppressive Agents	\$2,324	1	3	\$774.80	\$0.26	-65.7%	-63.4%	0.6%
12	11	ENOXAPARIN SODIUM	Injectable Anticoagulants	\$588	1	1	\$588.00	\$0.07	-74.3%	-58.8%	0.2%
13	6	VIREAD	HIV-NRTI	\$0	0	0	\$0.00	\$0.00	-100.0%	-100.0%	0.0%
Totals:				\$382,729		67	\$5,712.38	\$42.39	21.0%	74.7%	100.0%
Specialty Plan Totals:				\$382,729		67	\$5,712.38	\$42.39	7.7%	36.4%	

* New meds not ranked previously for this time frame comparison

Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Specialty Analysis - BrivoRx®



Top Specialty Classes	Rx Volume					
	Brivo	% Total	Retail	Retail %	Other	Other %
Chronic Inflammatory Disease	29	100.0%	0	0.0%	0	0.0%
HIV-NRTI	11	100.0%	0	0.0%	0	0.0%
Oncology	10	100.0%	0	0.0%	0	0.0%
Muscle Relaxants & Combos	4	100.0%	0	0.0%	0	0.0%
Immunosuppressive Agents	3	100.0%	0	0.0%	0	0.0%

Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Specialty Analysis - Copay Assistance at BriovaRx®

71.0%

of Member Paid is Covered
by Copay Assistance

75.1%


Copay Coverage
Previous Period

4.1%

Percent Change

**Copay Assistance is provided on 71.0%
of Briova scripts**

Copay Assistance Over Time



Top Specialty Drugs with Copay Assistance	Member Paid Share		Copay Assistance	Net Out of Pocket		
	Rxs	Total	Total	Total	Pct	Total Per Rx
HUMIRA PEN	8	\$1,588	\$1,547	\$41	2.6%	\$5.16

4. Supplemental

Bakers Union and FELRA Health and Welfare Fund

Date Filled: Jan 2018 - Dec 2018

Clinical Outcomes

18.4%


Percent Plan Paid Savings

			Savings		
Clinical Program	Number of Interventions	Number of Members Impacted	Total Plan Paid	Pct Plan Paid	Plan Paid PMPM
Prior Authorization	18	15	\$163,542	16.9%	\$18.11
Quantity Limit	4	4	\$4,702	0.5%	\$0.52
Step Therapy	15	13	\$10,418	1.1%	\$1.15
Total Savings:			\$178,662	18.4%	\$19.79

5. Clinical Opportunity - Vigilant Drug Program

Vigilant Drug Program


- Flexibility in exclusions and strategies for quality and value



Vigilant Drug Program

- Clinical quality exclusion strategies promote safety and savings


Me Too and Non-Essential strategies can uncover unnecessary spend
Drive use of covered formulary alternatives



Vigilant Drug Program

- Cost-saving exclusion strategies lead to significant savings

High-Cost Generics and High-Cost Brands with Generics exclusion strategies promotes the use of lower-cost generic options



Vigilant Impact Analysis

Bakers Union and FELRA Health and Welfare Fund - 01/01/18 – 12/31/18

Non-FDA Approved Drugs

11	19	\$352	\$4,842
Utilizers	Rxs	Member Paid	Plan Paid

Me Too Drugs

8	10	\$300	\$9,226
Utilizers	Rxs	Member Paid	Plan Paid

Pain Creams & Patches

1	4	\$120	\$1,693
Utilizers	Rxs	Member Paid	Plan Paid

High Cost Generics

4	26	\$255	\$3,124
Utilizers	Rxs	Member Paid	Plan Paid

High Cost Brands with Generics

1	1	\$15	\$136
Utilizers	Rxs	Member Paid	Plan Paid

Medical Benefit Specialty

0	0	\$0	\$0
Utilizers	Rxs	Member Paid	Plan Paid

Total Utilizers	Total Rxs	Total Member Paid	Total Plan Paid
24	60	\$1,042	\$19,022
4.6% of total	0.7% of total	1.2% of total	2.0% of total


Vigilant Impact Analysis

Bakers Union and FELRA Health and Welfare Fund - 01/01/18 – 12/31/18

Drug Summary

Disease Category	Generic Name	Brand Name	Vigilant Drug List	Utilizers	Rxs	Ingredient Cost	Plan Paid
Ulcer/Acid Reflux/Gerd	ESOMEPRAZOLE MAGNESIUM	ESOMEPRAZOLE MAGNESIUM	HCGEN	4	26	\$3,347.08	\$3,124.38
Misc Skin Condition	UREA	UREA	NONFDA	4	5	\$617.62	\$573.12
Rectal Preparations	HYDROCORTISONE ACETATE (RECTAL)	HYDROCORTISONE ACETATE	NONFDA	2	2	\$563.79	\$544.58
Ear Condition	CIPROFLOXACIN-FLUOCINOLONE ACETONIDE	OTOVEL	METOO	2	3	\$701.05	\$613.95
Misc Skin Condition	HALCINONIDE	HALOG	METOO	1	2	\$1,521.02	\$1,463.62
		HYDROCORTISONE					
Rectal Preparations	HYDROCORTISONE ACETATE W/ PRAMOXINE	ACETATE/PRAMOXINE	NONFDA	1	4	\$644.95	\$609.65
Misc Skin Condition	DERMATOLOGICAL PRODUCTS, MISC.	HYLATOPIC PLUS	NONFDA	1	4	\$1,808	\$1,693
Misc Skin Condition	DERMATOLOGICAL PRODUCTS, MISC.	HYLATOPIC PLUS	PCPATCH	1	4	\$1,807.84	\$1,692.54
Topical Anti-Fungal	LULICONAZOLE	LUZU	METOO	1	1	\$486.01	\$457.31
Misc Skin Condition	DERMATOLOGICAL PRODUCTS, MISC.	NUVAIL	NONFDA	1	1	\$389.56	\$360.86
Topical Anti-Fungal	OXICONAZOLE NITRATE	OXISTAT	METOO	1	1	\$644.18	\$615.48
	PRENATAL W/O A W/ FE ASPARTO GLYC-L						
Vitamins, Minerals, Electrolytes	METHYLFOLATE-FA-DHA	PRENATE DHA	NONFDA	1	2	\$398.96	\$341.56
Anti-Inflammatory (Steroids)	PREDNISONE	RAYOS	METOO	1	1	\$4,957.95	\$4,929.25
Misc Skin Condition	BENZOYL PEROXIDE	RIAX	METOO	1	1	\$460.22	\$431.52
Antivirals	OSELTAMIVIR PHOSPHATE	TAMIFLU	HCBRWGEN	1	1	\$150.00	\$136.30
Misc Skin Condition	UREA	UTOPIC	NONFDA	1	1	\$748.60	\$719.90
Non-Narcotic Analgesics	NAPROXEN-ESOMEPRAZOLE MAGNESIUM	VIMOVO	METOO	1	1	\$743.66	\$714.96

Vigilant Drug Program savings



6. Clinical Opportunity - Vigilant Drug Program (Rx w/OTC)

Rx with OTC Exclusion Strategy

- Focus on clinical quality and savings

Provides access to clinically appropriate medications while driving to lowest net cost

- Optional list excludes certain prescription products when therapeutically acceptable over-the-counter (OTC) alternatives are available
- Excludes frequently used Rx and OTC products within targeted drug classes
- Focuses on products with high prescription fill volume, various dosage forms and strengths, and those often resulting in higher client drug spend

Clients can save up to \$1.01
PMPM in ingredient costs



~40 brand drugs and ~20 generic drugs



5 drug classes: H-2 Antagonists, Nasal Steroids, Non-Sedating Antihistamines, Proton-Pump Inhibitors and Miscellaneous Laxatives

Rx with OTC Exclusion Strategy

Bakers Union and FELRA Health and Welfare Fund - 01/01/18 – 12/31/18

Rx With OTC

64 224 \$2,437 \$17,293

Utilizers Rxs Member Paid Plan Paid

Drug Summary

Disease Category	Generic Name	Brand Name	Utilizers	Rxs	Ingredient Cost	Plan Paid
	FLUTICASONE PROPIONATE					
Allergies	(NASAL)	FLUTICASONE PROPIONATE	32	60	\$954.64	\$503.14
Allergies	CETIRIZINE HCL	CETIRIZINE HCL	7	8	\$28.04	\$0.73
	ESOMEPRAZOLE	ESOMEPRAZOLE				
Ulcer/Acid Reflux/Gerd	MAGNESIUM	MAGNESIUM	4	26	\$3,347.08	\$3,124.38
Ulcer/Acid Reflux/Gerd	FAMOTIDINE	FAMOTIDINE	4	4	\$16.19	\$1.10
Ulcer/Acid Reflux/Gerd	LANSOPRAZOLE	LANSOPRAZOLE	4	35	\$2,759.11	\$2,451.61
Ulcer/Acid Reflux/Gerd	DEXLANSOPRAZOLE	DEXILANT	3	28	\$7,579.56	\$6,884.56
	LEVOCETIRIZINE	LEVOCETIRIZINE				
Allergies	DIHYDROCHLORIDE	DIHYDROCHLORIDE	3	27	\$2,844	\$2,608
Allergies	LORATADINE	LORATADINE	3	5	\$12.50	\$0.00
	MOMETASONE FUROATE					
Allergies	(NASAL)	MOMETASONE FUROATE	3	4	\$1,285.23	\$1,249.93
	POLYETHYLENE GLYCOL					
Gastrointestinal, Misc	3350	POLYETHYLENE GLYCOL 3350	3	3	\$97.81	\$71.82
Allergies	CETIRIZINE HCL	CETIRIZINE HYDROCHLORIDE	2	2	\$9.98	\$0.00
Allergies	LORATADINE	LORATADINE CHILDRENS	2	2	\$16.87	\$2.54
Ulcer/Acid Reflux/Gerd	RANITIDINE HCL	RANITIDINE HCL	2	4	\$37.17	\$7.90
Ulcer/Acid Reflux/Gerd	RANITIDINE HCL	RANITIDINE HYDROCHLORIDE	2	6	\$28.78	\$0.00
Allergies	LORATADINE	ALLERGY	1	8	\$24.01	\$0.00
	BECLOMETHASONE					
Allergies	DIPROPIONATE (NASAL)	QNASL	1	2	\$414.16	\$386.76

7. Clinical Opportunity - Diabetes Program

Controlling diabetes

- Can improve health and lower health care costs



People with diagnosed diabetes

- Take more prescription drugs
- Visit doctor offices and emergency rooms more frequently¹
- May also have cardiovascular, kidney or eye disease, cancer, obesity, hypertension, fractures or amputations


Average cost for diabetic members
is **~\$17,000 per year¹**

Patients with controlled diabetes may
see a **10% decrease in costs²**

People with controlled diabetes

- Have fewer hospitalization and emergency room visits
- Maintain a healthy lifestyle, including diet and exercise
- Adhere to medications
- Regularly test blood glucose levels and participate in preventive screenings






DIABETIC UTILIZERS: 60
TOTAL UTILIZERS: 517

High risk diabetic utilizers have **\$1,589** higher annualized plan paid than low risk diabetic utilizers¹


Average Annual Pharmacy Plan Paid



Pharmacy Utilizers

3% of Pharmacy Utilizers filled a SGLT-2, GLP-1, or DPP-4 inhibitor

■ Non-Diabetics ■ Low Risk Diabetics
■ High Risk Diabetics



Pharmacy Plan Paid

33% of Pharmacy Plan Paid attributed to diabetic members


■ Non-Diabetics ■ Low Risk Diabetics
■ High Risk Diabetics

Diabetics in current period vs. prior period

12% new diabetic utilizers


Changing diabetic regimen is defined as either adding a DPP-4, GLP-1, or SGLT-2 where one was not previously used or discontinuing these medications

*Unclassified indicates data not available for prior period




■ Unclassified ■ New Diabetics ■ Stable Therapy ■ Therapy Change

Diabetic member co-morbidities²



of total Diabetics



²Pharmacy claims used as an indicator of disease. Drugs could be used for other purposes.

OptumRx Diabetes Management Program Summary

PROGRAM AVAILABILITY

- Available starting 1/1/19
- Implement on calendar quarterly basis
- 60 day implementation window required

PROVIDED TO ENTIRE MEMBERSHIP

- Adherence monitoring
 - **Members:** New to therapy education, refill reminders
 - **Prescribers:** Primary non-adherence and Low Adherence outreach to prescribers
- Gaps in care closure through prescriber outreach

PROVIDED TO HIGH-RISK MEMBERS

Program can expect to save \$1,700 per high-risk member

- Up to 4 sessions per plan year
- 1:1 coaching session on diabetes management, lifestyle, diet, nutrition and medication reconciliation
- Smart meter with cloud connectivity and access of patients testing data during 1:1 coaching
- Option for copay waiver on diabetic supplies
- Client billed on a quarterly basis

Prospective Analysis Dashboard

High Risk Member Selection

Benefit Design & Program Consideration	High Risk %	High Risk Members	Expected Engagement of 25%		Est. Program Fees
	15	9	3	x \$195 annual per counseling charge =	\$585
Counseling for top high risk diabetes utilizers					\$585
Adherence monitoring (\$0.06 PMPM)	.06 Total Per Member Per Month (PMPM)				\$593
Gaps in care monitoring (\$0.02 PMPM)	.02 Total Per Member Per Month (PMPM)				\$198
Total Program Cost					\$1,376

Total member population = 824

Total diabetes utilizers = 60

8. Clinical Opportunity/ Utilization Management Focus/Comprehensive

Focus UM's Analysis

report date: 1/1/18 to 12/31/18

Savings Category	Estimated Annualized Savings
Utilization Management Pharmacy Savings:	\$1,670
Total Savings	\$1,670
Utilization Management Strategy	Estimated Pharmacy Savings*
	Annualized
Prior Authorization (PA)	\$568
Step Therapy (ST)	\$1,103
Quantity Limit (QL)	\$0
Total Savings	\$1,670

Focus UM's Analysis

report date: 1/1/18 to 12/31/18

Prior Authorization Drug Summary

PA – Total Utilizing member = 7

Rank	Drug Name	Therapeutic Class	Utilizing Member Count	Claim Rx Count
1.)	MORPHINE SULFATE ER	OPIOID AGONISTS	1	12
2.)	OXYCONTIN	OPIOID AGONISTS	2	3
3.)	BUTRANS	OPIOID PARTIAL AGONISTS	1	3
4.)	EMBEDA	OPIOID AGONISTS	1	2
5.)	HYSINGLA ER	OPIOID AGONISTS	1	2
6.)	XTAMPZA ER	OPIOID AGONISTS	1	2

Step Therapy Drug Summary

ST – Total Utilizing member = 7

Rank	Drug Name	Therapeutic Class	Utilizing Member Count	Claim Rx Count
1.)	LINZESS	IRRITABLE BOWEL SYNDROME (IBS) AGENTS	2	4
2.)	TUDORZA PRESSAIR	BRONCHODILATORS - ANTICHOLINERGICS	1	3
3.)	AMITIZA	GASTROINTESTINAL CHLORIDE CHANNEL ACTIVATORS	1	3
4.)	ACANYA	ACNE PRODUCTS	2	2
5.)	BASAGLAR KWIKPEN	INSULIN	1	1

Comprehensive UM's Analysis

report date: 1/1/18 to 12/31/18

Savings Category	Estimated Annualized Savings
Utilization Management Pharmacy Savings:	\$23,680
Total Savings	\$23,680
Utilization Management Strategy	Estimated Pharmacy Savings*
	Annualized
Prior Authorization (PA)	\$18,045
Step Therapy (ST)	\$4,156
Quantity Limit (QL)	\$1,479
Total Savings	\$23,680

Comprehensive UM's Analysis

report date: 1/1/18 to 12/31/18

Prior Authorization Drug Summary

Rank	Drug Name	Therapeutic Class	Specialty Flag	Utilizing Member Count	Claim Rx Count
1.)	SIMVASTATIN	HMG COA REDUCTASE INHIBITORS	N	2	17
2.)	MORPHINE SULFATE ER	OPIOID AGONISTS	N	1	12
3.)	GUAIAUSSIN AC	COUGH/COLD/ALLERGY COMBINATIONS	N	9	10
4.)	IBRANCE	ANTINEOPLASTIC ENZYME INHIBITORS	Y	1	9
5.)	METHYLPHENIDATE HYDROCHLORIDE ER	ADHD & NARCOLEPSY MEDICATIONS	N	1	8
6.)	PROMETHAZINE/CODEINE	COUGH/COLD/ALLERGY COMBINATIONS	N	8	8
7.)	RESTASIS	OPHTHALMIC IMMUNOMODULATORS	N	3	8
8.)	HYDROCODONE POLISTIREX/CHLORPHENIRAMINE POLISTIREX	COUGH/COLD/ALLERGY COMBINATIONS	N	6	6
9.)	CODEINE/GUAIFENESIN	COUGH/COLD/ALLERGY COMBINATIONS	N	6	6
10.)	VYVANSE	AMPHETAMINES	N	1	5
11.)	AMPHETAMINE/DEXTROAMPHETAMINE	AMPHETAMINES	N	3	5
12.)	CONTRAVE	ANTI-OBESITY AGENTS	N	2	4
13.)	BOTOX	NEUROMUSCULAR BLOCKING AGENT - NEUROTOXINS	Y	1	4
14.)	CHERATUSSIN AC	COUGH/COLD/ALLERGY COMBINATIONS	N	4	4
15.)	OXYCONTIN	OPIOID AGONISTS	N	2	3
16.)	BUTRANS	OPIOID PARTIAL AGONISTS	N	1	3
17.)	ABSORICA	ACNE PRODUCTS	N	1	3
18.)	ADAPALENE	ACNE PRODUCTS	N	1	3
19.)	TRETINOIN	ACNE PRODUCTS	N	2	2
20.)	HYSINGLA ER	OPIOID AGONISTS	N	1	2
21.)	RETIN-A MICRO PUMP	ACNE PRODUCTS	N	1	2
22.)	MYORISAN	ACNE PRODUCTS	N	1	2
23.)	XIIDRA	OPHTHALMIC INTEGRIN ANTAGONISTS	N	2	2
24.)	XTAMPZA ER	OPIOID AGONISTS	N	1	2
25.)	QUININE SULFATE	ANTIMALARIALS	N	1	2
26.)	EMBEDA	OPIOID AGONISTS	N	1	2
27.)	DEXTROAMPHETAMINE SULFATE ER	AMPHETAMINES	N	1	2
28.)	HYDROCODONE BITARTRATE/HOMATROPINE METHYLBROMIDE	ANTITUSSIVES	N	1	1
29.)	GUAIFENESIN/CODEINE	COUGH/COLD/ALLERGY COMBINATIONS	N	1	1
30.)	VIMOVO	NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (NSAIDS)	N	1	1
31.)	JUBLIA	ANTIFUNGALS - TOPICAL	N	1	1

Comprehensive UM's Analysis

report date: 1/1/18 to 12/31/18

Step Therapy Drug Summary

Rank	Drug Name	Therapeutic Class	Specialty Flag	Utilizing Member Count	Claim Rx Count
1.)	LIVALO	HMG COA REDUCTASE INHIBITORS	N	1	12
2.)	TRINTELLIX	SEROTONIN MODULATORS	N	2	9
3.)	ULORIC	GOUT AGENTS	N	1	9
4.)	TROKENDI XR	ANTICONSULSANTS - MISC.	N	2	9
5.)	COLCHICINE	GOUT AGENTS	N	3	5
6.)	ELIDEL	IMMUNOSUPPRESSIVE AGENTS - TOPICAL	N	2	4
7.)	LINZESS	IRRITABLE BOWEL SYNDROME (IBS) AGENTS	N	2	4
8.)	TUDORZA PRESSAIR	BRONCHODILATORS - ANTICHOLINERGICS	N	1	3
9.)	AMITIZA	GASTROINTESTINAL CHLORIDE CHANNEL ACTIVATORS	N	1	3
10.)	EUCRISA	PHOSPHODIESTERASE 4 (PDE4) INHIBITORS - TOPICAL	N	2	2
11.)	ACANYA	ACNE PRODUCTS	N	2	2
12.)	BASAGLAR KWIKPEN	INSULIN	N	1	1
13.)	CIPROFLOXACIN	OTIC ANTI-INFECTIVES	N	1	1

ST –

Total Utilizing member = 21

Comprehensive UM's Analysis

report date: 1/1/18 to 12/31/18

Quantity Limit Drug Summary

Rank	Drug Name	Therapeutic Class	Specialty Flag	Utilizing Member Count Above the Quantity Limit	Claim Rx Count above the Quantity Limit
1.)	LATANOPROST SOL 0.005%	PROSTAGLANDINS - OPHTHALMIC	N	2	11
2.)	SILDENAFIL TAB 100MG	IMPOTENCE AGENTS	N	4	11
3.)	CIALIS TAB 20MG	IMPOTENCE AGENTS	N	3	11
4.)	OSELTAMIVIR CAP 75MG	INFLUENZA AGENTS	N	10	10
5.)	OXYCOD/APAP TAB 5-325MG	OPIOID COMBINATIONS	N	9	9
6.)	TRAMADOL HCL TAB 100MG ER	OPIOID AGONISTS	N	1	7
7.)	OXYCODONE TAB 10MG	OPIOID AGONISTS	N	4	6
8.)	TERBINAFINE TAB 250MG	ANTIFUNGALS	N	3	6
9.)	SYMBICORT AER 160-4.5	SYMPATHOMIMETICS	N	1	4
10.)	PROLENSA SOL 0.07%	OPHTHALMICS - MISC.	N	3	4
11.)	TADALAFIL TAB 20MG	IMPOTENCE AGENTS	Y	2	3
12.)	HYDROCO/APAP TAB 5-325MG	OPIOID COMBINATIONS	N	3	3
13.)	OLANZAPINE TAB 5MG	DIBENZAPINES	N	2	3
14.)	CHANTIX PAK 0.5& 1MG	SMOKING DETERRENTS	N	2	3
15.)	HYDROMORPHON TAB 2MG	OPIOID AGONISTS	N	2	2
16.)	LOTEMAX GEL 0.5%	OPHTHALMIC STEROIDS	N	2	2
17.)	HYDROCO/APAP TAB 10-325MG	OPIOID COMBINATIONS	N	1	2
18.)	SILDENAFIL TAB 50MG	IMPOTENCE AGENTS	N	1	2
19.)	OXYCOD/APAP TAB 10-325MG	OPIOID COMBINATIONS	N	2	2
20.)	CHANTIX TAB 1MG	SMOKING DETERRENTS	N	1	2
		NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (NSAIDS)			
21.)	KETOROLAC TAB 10MG	NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (NSAIDS)	N	2	2
22.)	OXYCODONE TAB 5MG	OPIOID AGONISTS	N	2	2
23.)	OSELTAMIVIR CAP 30MG	INFLUENZA AGENTS	N	1	1
24.)	MOMETASONE SPR 50MCG	NASAL STEROIDS	N	1	1
25.)	CHANTIX PAK 1MG	SMOKING DETERRENTS	N	1	1
26.)	VALACYCLOVIR TAB 500MG	HERPES AGENTS	N	1	1
27.)	ALBUTEROL NEB 0.083%	SYMPATHOMIMETICS	N	1	1
28.)	VENTOLIN HFA AER	SYMPATHOMIMETICS	N	1	1
29.)	ARIPRAZOLE TAB 15MG	QUINOLINONE DERIVATIVES	N	1	1
30.)	ADVAIR HFA AER 230/21	SYMPATHOMIMETICS	N	1	1
31.)	TAMIFLU CAP 75MG	INFLUENZA AGENTS	N	1	1
32.)	ENOXAPARIN INJ 40/0.4ML	INJECTABLE ANTICOAGULANTS	Y	1	1
33.)	MORPHINE SUL TAB 15MG	OPIOID AGONISTS	N	1	1

Summary

Program	Program Savings	Percentage of Plan Paid	Potential Member Impact
Vigilant Drug Programs**	\$ 19,022*	1.9%	24 utilizers
Vigilant Drug Programs Rx w/OTC**	\$17,293*	1.7%	64 utilizers
Diabetes Program**	\$9,000*	10%	60 utilizers
Utilization Management – Focus**	\$1,670	1%	14 utilizers
Utilization Management – Comprehensive**	\$23,680	2.4%	162 utilizers
Total Savings	\$70,665	7.3%	

9. Appendix

retail vs mail vs specialty - Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Description	Retail			Mail			Specialty		
	Jan 18 - Dec 18	Jan 17 - Dec 17	Pct Change	Jan 18 - Dec 18	Jan 17 - Dec 17	Pct Change	Jan 18 - Dec 18	Jan 17 - Dec 17	Pct Change
Average Eligible Members	752	774	-2.8%	752	774	-2.8%	752	774	-2.8%
Total Plan Paid	\$556,409	\$584,398	-4.8%	\$30,391	\$37,076	-18.0%	\$382,729	\$288,804	32.5%
Percent of Total Plan Paid	57.4%	64.2%	-10.6%	3.1%	4.1%	-23.0%	39.5%	31.7%	24.4%
Total Rxs	8,707	9,283	-6.2%	103	159	-35.2%	67	64	4.7%
Plan Paid PMPM	\$61.63	\$62.90	-2.0%	\$3.37	\$3.99	-15.6%	\$42.39	\$31.08	36.4%
Plan Paid per Rx	\$63.90	\$62.95	1.5%	\$295.06	\$233.18	26.5%	\$5,712.38	\$4,512.56	26.6%
Rxs PMPM	0.96	1.00	-3.5%	0.01	0.02	-33.3%	0.01	0.01	7.7%
Generic Dispensing Rate	84.3%	82.5%	2.2%	87.4%	93.7%	-6.8%	22.4%	20.3%	10.2%
Member Paid Share	12.5%	13.0%	-3.5%	5.4%	6.0%	-10.1%	0.6%	0.7%	-14.8%
Member Paid per Rx	\$9.14	\$9.37	-2.5%	\$16.71	\$14.77	13.1%	\$34.45	\$31.97	7.8%

retail vs retail 90 vs mail - Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Description	Results Exclude Specialty Claims								
	Retail 30			Retail 90			Mail		
	Jan 18 - Dec 18	Jan 17 - Dec 17	Pct Change	Jan 18 - Dec 18	Jan 17 - Dec 17	Pct Change	Jan 18 - Dec 18	Jan 17 - Dec 17	Pct Change
Average Eligible Members	752	774	-2.8%	752	774	-2.8%	752	774	-2.8%
Total Plan Paid	553,545	581,327	-4.8%	2,864	3,071	-6.7%	30,391	37,076	-18.0%
Percent of Total Plan Paid	57.1%	63.9%	-10.6%	0.3%	0.3%	-12.4%	3.1%	4.1%	-23.0%
Total Rxs	8,688	9,256	-6.1%	19	27	-29.6%	103	159	-35.2%
Percent of Total Rxs	97.9%	97.4%	0.5%	0.2%	0.3%	-24.6%	1.2%	1.7%	-30.6%
Plan Paid PMPM	\$61.31	\$62.57	-2.0%	\$0.32	\$0.33	-4.0%	\$3.37	\$3.99	-15.6%
Plan Paid per Rx	\$63.71	\$62.81	1.4%	\$150.75	\$113.74	32.5%	\$295.06	\$233.18	26.5%
Rxs PMPM	0.96	1.00	-3.4%	0.00	0.00	-27.6%	0.01	0.02	-33.3%
Generic Dispensing Rate	84.2%	82.4%	2.2%	100.0%	100.0%	0.0%	87.4%	93.7%	-6.8%
Member Paid Share	12.6%	13.0%	-3.5%	2.3%	1.1%	118.0%	5.4%	6.0%	-10.1%
Member Paid per Rx	\$9.15	\$9.40	-2.6%	\$3.61	\$1.23	192.7%	\$16.71	\$14.77	13.1%

key performance by quarter - Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Description	Bakers Union and FELRA Health and Welfare Fund				
	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4
Average Eligible Members	741	743	759	767	772
Total Utilizers	333	348	355	353	372
Percent Total Utilizers	45.0%	46.9%	46.8%	46.0%	48.2%
Total Plan Paid	\$231,876	\$234,037	\$253,183	\$250,495	\$298,689
Total Rxs	2,168	2,203	2,250	2,257	2,444
Plan Paid PMPM	\$104.35	\$105.04	\$111.24	\$108.82	\$128.97
Plan Paid per Rx	\$106.95	\$106.24	\$112.53	\$110.99	\$122.21
Rxs PMPM	0.98	0.99	0.99	0.98	1.06
Member Paid Share	8.0%	7.6%	7.7%	8.4%	6.9%
Generic Dispensing Rate	82.9%	84.7%	83.8%	83.9%	81.5%
Mail Order Rate	1.0%	1.0%	1.2%	1.4%	1.6%
Average Days Supply	26.6	26.5	26.6	26.6	26.2
Specialty Plan Paid PMPM	\$43.32	\$36.76	\$41.67	\$47.66	\$61.75
Percent of Specialty Plan Paid	41.5%	35.0%	37.5%	43.8%	47.9%

top disease categories by plan paid - Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Curr Rank	Prev Rank	Disease Category Name	Jan 18 - Dec 18								
			Plan Paid	Utilizers	Rxs	Plan Paid per Rx	GDR	Plan Paid PMPM	Avg Plan Paid Pct Change	Rxs PMPM Pct Change	Plan Paid PMPM Pct Change
1	1	Inflammatory Conditions	\$191,522	5	30	\$6,384.05	3.3%	\$21.21	27.4%	-0.4%	26.9%
2	2	Diabetes	\$136,248	60	754	\$180.70	65.1%	\$15.09	-7.5%	8.1%	0.0%
3	7	Oncology	\$119,543	5	39	\$3,065.21	74.4%	\$13.24	306.6%	-16.4%	240.0%
4	5	Asthma / COPD	\$44,592	66	269	\$165.77	32.0%	\$4.94	25.3%	-20.0%	0.2%
5	4	Cardiovascular	\$44,483	156	1,936	\$22.98	94.2%	\$4.93	-13.5%	-1.3%	-14.5%
6	11	Misc Skin Condition	\$37,690	86	176	\$214.15	79.0%	\$4.17	32.8%	16.1%	54.2%
7	6	Erectile Dysfunction	\$33,669	22	129	\$261.00	65.1%	\$3.73	-8.6%	1.3%	-7.3%
8	10	HIV	\$32,425	2	19	\$1,706.59	57.9%	\$3.59	13.0%	15.0%	30.0%
9	3	Hepatitis	\$32,304	1	1	\$32,304.00	0.0%	\$3.58	0.0%	-48.5%	-48.5%
10	8	Cholesterol Low ering Agents	\$27,800	105	848	\$32.78	97.2%	\$3.08	-8.4%	-4.9%	-12.9%
Totals:			\$700,276		4,201	\$166.69	83.1%	\$77.57	18.5%	-1.4%	16.9%
Plan Totals:			\$969,529		8,877	\$109.22	83.8%	\$107.39	14.1%	-3.9%	9.6%

top drugs by plan paid - Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Curr Rank	Prev Rank	Drug Name	Therapeutic Class Name	Jan 18 - Dec 18							
				Plan Paid	Utilizers	Rxs	Plan Paid Per Rx	Plan Paid PMPM	Rxs PMPM Pct Change	Plan Paid PMPM Pct Change	Pct Total Plan Paid
1	3	IBRANCE	Oncology	\$118,957	1	10	\$11,895.74	\$13.18	243.0%	255.0%	12.3%
2		TREMFYA	Chronic Inflammatory Disease	\$94,795	2	9	\$10,532.77	\$10.50			9.8%
3	1	HUMIRA PEN	Chronic Inflammatory Disease	\$38,548	2	8	\$4,818.49	\$4.27	-54.3%	-50.3%	4.0%
4	2	HARVONI	Hepatitis C	\$32,304	1	1	\$32,304.00	\$3.58	-48.5%	-48.5%	3.3%
5	13	XELJANZ XR	Chronic Inflammatory Disease	\$29,813	1	7	\$4,259.02	\$3.30	140.1%	162.1%	3.1%
6	6	HUMALOG MIX 50/50 KWIKPEN	Insulin	\$25,564	2	26	\$983.21	\$2.83	-13.7%	37.6%	2.6%
7	12	STRIBILD	HIV-Multiclass Combo	\$23,878	1	8	\$2,984.72	\$2.64	105.8%	109.0%	2.5%
8		SIMPONI ARIA	Chronic Inflammatory Disease	\$21,274	1	3	\$7,091.24	\$2.36			2.2%
9	8	LYRICA	Anticonvulsants - 2nd Generation	\$18,064	7	45	\$401.43	\$2.00	5.3%	12.5%	1.9%
10	7	CIALIS	Impotence Agents	\$14,123	9	42	\$336.27	\$1.56	-40.0%	-21.7%	1.5%
11	137	SILDENAFIL CITRATE	Impotence Agents	\$13,975	13	67	\$208.59	\$1.55	1,623.8%	1,025.4%	1.4%
12	15	ARIPRAZOLE	Atypical Antipsychotics	\$13,658	3	12	\$1,138.17	\$1.51	208.7%	28.9%	1.4%
13	33	JARDIANCE	SGLT-2 Inhibitors & Combos	\$12,912	3	29	\$445.26	\$1.43	86.5%	101.8%	1.3%
14	45	REXULTI	Atypical Antipsychotics	\$10,816	1	11	\$983.29	\$1.20	88.7%	131.3%	1.1%
15	29	INVOKANA	SGLT-2 Inhibitors & Combos	\$9,894	2	17	\$582.02	\$1.10	-2.8%	40.8%	1.0%
16	11	JANUVIA	DPP-4 Inhibitors & Combos	\$9,818	3	24	\$409.09	\$1.09	-22.8%	-15.1%	1.0%
17	18	LIDOCAINE	Local Anesthetics - Topical	\$9,011	11	27	\$333.75	\$1.00	11.1%	-0.3%	0.9%
18	31	VICTOZA	Injectable Diabetic Meds	\$8,970	1	12	\$747.48	\$0.99	-5.0%	35.8%	0.9%
19	14	SYMBICORT	Inhaled Asthma/COPD Combo	\$8,935	8	29	\$308.11	\$0.99	-21.5%	-16.9%	0.9%
20	48	BREO ELLIPTA	Inhaled Asthma/COPD Combo	\$8,834	4	22	\$401.55	\$0.98	50.9%	108.3%	0.9%
Totals:				\$524,145		409	\$1,281.53	\$58.06	21.0%	63.1%	54.1%
Plan Totals:				\$969,529		8,877	\$109.22	\$107.39	-3.9%	9.6%	

top drugs by rxs - Bakers Union and FELRA Health and Welfare Fund

Date Submitted: Jan 18 - Dec 18 vs Jan 17 - Dec 17

Curr Rank	Prev Rank	Drug Name	Therapeutic Class Name	Jan 18 - Dec 18							
				Plan Paid	Utilizers	Rxs	Plan Paid per Rx	Plan Paid PMPM	Rxs PMPM Pct Change	Plan Paid PMPM Pct Change	Pct Total Plan Paid
1	1	ATORVASTATIN CALCIUM	Statins & Combos	\$5,615	58	400	\$14.04	\$0.62	-6.7%	-38.5%	0.6%
2	2	LISINAPRIL	ACE Inhibitors & Combos	\$28	50	344	\$0.08	\$0.00	11.0%		0.0%
3	3	VITAMIN D	Vitamins & Supplements	\$28	61	269	\$0.10	\$0.00	7.3%	-69.4%	0.0%
4	4	LEVOTHYROXINE SODIUM	Thyroid Hormones	\$2,033	30	247	\$8.23	\$0.23	0.1%	-5.2%	0.2%
5	6	METOPROLOL SUCCINATE ER	Beta Blockers & Combos	\$4,497	25	210	\$21.41	\$0.50	32.6%	50.4%	0.5%
6	7	METFORMIN HCL	Biguanides & Combos	\$47	21	165	\$0.28	\$0.01	11.0%	26.0%	0.0%
7	5	AMLODIPINE BESYLATE	Calcium Channel Blockers	\$39	28	155	\$0.25	\$0.00	-10.9%	-24.4%	0.0%
8	9	ROSUVASTATIN CALCIUM	Statins & Combos	\$4,077	21	148	\$27.55	\$0.45	9.6%	-22.8%	0.4%
9	8	SIMVASTATIN	Statins & Combos	\$363	15	124	\$2.93	\$0.04	-9.5%	-9.7%	0.0%
10	10	HYDROCHLOROTHIAZIDE	Diuretics & Combos	\$28	14	120	\$0.23	\$0.00	-11.2%	-27.8%	0.0%
11	14	LISINAPRIL/HYDROCHLOROTHIAZIDE	ACE Inhibitors & Combos	\$0	14	108	\$0.00	\$0.00	7.9%		0.0%
12	13	AMOXICILLIN	Penicillins	\$21	76	100	\$0.21	\$0.00	-2.9%	275.2%	0.0%
13	11	IBUPROFEN	Nonsteroidal Anti-Inflammatory Agents (NSAIDs)	\$23	68	98	\$0.24	\$0.00	-18.7%	681.9%	0.0%
14	12	LOSARTAN POTASSIUM/HYDROCHLOROTHIAZIDE	Angiotensin II Receptor Antagonists & Combos	\$937	16	96	\$9.76	\$0.10	-11.8%	-29.1%	0.1%
15	15	AZITHROMYCIN	Macrolides	\$531	69	92	\$5.77	\$0.06	-7.2%	14.4%	0.1%
16	17	SERTRALINE HCL	Antidepressants	\$230	17	92	\$2.50	\$0.03	4.0%	52.6%	0.0%
17	25	ESCITALOPRAM OXALATE	Antidepressants	\$1,161	13	84	\$13.82	\$0.13	27.1%	-22.0%	0.1%
18	24	METFORMIN HYDROCHLORIDE	Biguanides & Combos	\$0	14	78	\$0.00	\$0.00	16.3%		0.0%
19	16	MONTELUKAST SODIUM	Leukotriene Modulators	\$1,163	22	70	\$16.62	\$0.13	-28.0%	-38.2%	0.1%
20	30	METFORMIN HCL ER	Biguanides & Combos	\$97	8	69	\$1.41	\$0.01	22.4%	-98.8%	0.0%
Totals:				\$20,919		3,069	\$6.82	\$2.32	1.3%	-37.7%	2.2%
Plan Totals:				\$969,529		8,877	\$109.22	\$107.39	-3.9%	9.6%	